Health · Full coverage
Personalized mRNA Vaccine Shows Breakthrough Success in Preventing Skin Cancer Recurrence
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
50% center
Center 1Right 1
First reported by Mako · 4 hours ago
What happened
A phase three trial shows a personalized mRNA vaccine combined with Keytruda effectively prevents skin cancer recurrence without new safety issues. The treatment, tailored to individual tumor mutations, may simplify production and reduce costs. Moderna and Merck stocks rose sharply after the results, with analysts forecasting substantial future revenues.
- 01Phase three trial proves personalized mRNA vaccine prevents skin cancer recurrence effectively.
- 021,137 patients treated with vaccine plus Keytruda showed no new safety signals.
- 03Vaccine tailored to tumor mutations but does not require patient cells, easing production.
- 04Technology is also being tested for other cancers like lung cancer.
- 05Moderna and Merck stocks surged after results; pricing and regulatory talks upcoming.
- 06Analysts expect the treatment to generate about $3 billion in revenue by 2035.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
Related stories
Cancer Vaccine Shows Promise, Leaving One Patient Disease-Free for More Than Six YearsJun 11, 2026Novocure Shares Surge Over 20% on Strong Q2 2026 Cancer Treatment Revenue BeatJul 23, 2026China Develops AI-Driven Personalized Cancer Vaccine Production Line to Cut Development Time to One DayJun 29, 2026International Project Creates Comprehensive Cancer Models to Advance Personalized TreatmentsAug 5, 2026New Targeted Therapies Revolutionize Breast Cancer Treatment and Survival in IsraelJul 5, 2026Israeli-led study reports major breakthrough in high-risk bladder cancer treatmentJun 14, 2026
